Opus Genetics, Inc. Common Stock (IRD)
PHARMACEUTICAL PREPARATIONS
Opus Genetics, Inc. Common Stock (IRD) is listed on Nasdaq, where it has traded since November 6, 2020.
- Listed On
- Nasdaq
- Listed Since
- November 6, 2020
- Employees
- 28
- Market Cap
- $403M
About Opus Genetics, Inc. Common Stock
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 100 institutions reported holding IRD, with 57.5 million shares worth $236.4 million in aggregate. The largest reported holder was Caligan Partners, with 6.1 million shares worth $25.0 million. Of the 5 largest holders listed below, 3 added shares and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Caligan Partners | 6,077,084 | $25M | Added 0.03% |
| Adage Capital Partners GP, | 6,029,775 | $25M | Unchanged |
| Vanguard | 3,755,350 | $15M | Added 36.36% |
| Bios Capital Management | 3,683,429 | $15M | Unchanged |
| BlackRock | 3,116,487 | $13M | Added 2009.44% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is IRD?
Opus Genetics, Inc. Common Stock (IRD) is listed on Nasdaq, where it has traded since November 6, 2020.
Who are the largest institutional holders of IRD?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of IRD were Caligan Partners, Adage Capital Partners GP, and Vanguard.
How many institutions own IRD?
100 institutions reported a position in IRD for the quarter ended June 30, 2026, worth $236.4 million in total.
Did institutions buy or sell IRD last quarter?
Of the 5 largest reported holders, 3 added shares and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for IRD.
Every reported institutional holder, plus insider and congressional trades in IRD, on SentiSense.